Biopharmaceuticals

Milan – October 09, 2026 -- WuXi Biologics is pitching a European manufacturing footprint of 54,000 L of drug-substance capacity in Dundalk, Ireland, plus a 12,000 L site in Wuppertal, Germany, to biopharma clients at CPHI Milan 2026, as Europe's biologics market is projected to grow from an estimated US$123.75 billion in 2025 to about US$269.65 billion by 2035.

The market is forecast to expand at a CAGR of 8.1% from 2026 to 2035. CPHI Milan 2026 brings together more than 62,000 pharmaceutical professionals and 2,900 exhibitors.

Dundalk hub runs 54,000 L across perfusion and fed-batch platforms

The Dundalk site operates under an HPRA GMP manufacturing license, supports EMA-approved commercial products and has served more than 10 clients. In 2026, it secured multiple new large-scale manufacturing projects and began the associated technology transfers.

Piscataway, N.J. – October 08, 2026 -- GenScript Biotech Corporation and NVIDIA have launched a global startup competition pairing wet lab validation with accelerated computing to push AI-driven drug discovery toward commercial proof points.

Up to six finalists will pitch before judges during JPM Week in January

The GenScript and NVIDIA Life Sciences Startup PitchFest opened applications today, with finalists confirmed in December. Up to six companies will be selected for a GenScript-hosted pitch event during JPM Week, competing before a panel of judges for a winning slot.

Hong Kong – October 08, 2026 -- Sisram Medical Ltd (1696.HK) has announced a share repurchase plan to buy back up to 1% of its total issued shares on the open market, citing confidence in its long-term growth trajectory.

Buyback plan allows cancellation or treasury retention of shares

Under the existing share repurchase mandate, repurchased shares may either be cancelled or held as treasury shares depending on future capital management needs. The plan will be executed subject to market conditions, with the Board stating it will balance business development priorities, strategic investment needs and financial flexibility.

First-half 2026 revenue climbs 3.6% to US$171.4 million

Sisram reported H1 2026 revenue of US$171.4 million, up 3.6% year-on-year. International markets excluding North America drove growth, rising 16.7% YoY to US$127.0 million, with APAC generating US$78.4 million, a 19.1% YoY increase.

New Haven, Conn. – October 08, 2026 -- Biohaven Ltd. (NYSE: BHVN) has signed a licensing and collaboration agreement with Ono Pharmaceutical Co., Ltd. (TYO: 4528), granting Ono exclusive rights to develop and commercialize Biohaven's MoDE pan IgG degrader portfolio across Japan, South Korea, Taiwan, and ASEAN member states.

Biohaven secures up to $100 million in near-term payments from Ono

The deal includes $80 million paid at execution and a further $20 million tied to a milestone expected within a year. Biohaven will also receive royalties of approximately 20 percent on net sales generated by Ono within the licensed territory. Biohaven retains all rights to the portfolio outside this region, including the United States, Europe, and China.

Suzhou – October 7, 2026 -- Suzhou Ribo Life Science (06938.HK) and its Swedish subsidiary Ribocure Pharmaceuticals AB have submitted a Phase I Clinical Trial Application in the European Union for RBD3133, a small interfering RNA (siRNA) therapeutic targeting the INHBE gene for overweight and obesity.

RBD3133 silences a gene linked to healthier fat distribution in human genetic studies

RBD3133 is designed to selectively suppress INHBE, which encodes the protein activin E. Human genetic data show that individuals with naturally occurring loss-of-function variants in INHBE exhibit healthier fat distribution, improved metabolic profiles, and a lower estimated risk of coronary heart disease and type 2 diabetes.

Shanghai – October 07, 2026 -- WuXi AppTec has secured its third consecutive Gold medal from EcoVadis, placing the pharmaceutical CRDMO among the top 5% of companies worldwide for sustainability performance.

EcoVadis scores companies across 21 criteria covering four pillars

The rating agency evaluates global supply-chain participants on Environment, Labor & Human Rights, Ethics, and Sustainable Procurement, with Gold medals reserved for the highest percentile tier. WuXi AppTec's repeat award signals sustained compliance across its value chain rather than a one-time achievement.

Delray Beach, Fla. – – October 07, 2026 -- The global Active Pharmaceutical Ingredients (API) market will grow from USD 149.02 billion in 2026 to USD 199.42 billion by 2031, a 6.0% compound annual growth rate, according to new data from MarketsandMarkets.

North America commands 43.1% of global API sales as domestic manufacturing investment accelerates

North America held the largest regional share of the API market in 2025 at 43.1%, driven by established pharmaceutical R&D infrastructure and rising investment in domestic production capacity. The US leads regional output in high-value and complex API development, supported by a dense base of pharmaceutical companies, contract manufacturing organizations, and specialized API producers.

Galway – October 07, 2026 -- Medtronic plc has fixed the final exchange ratio for its split-off of MiniMed Group, Inc. at 4.5939 shares of MiniMed common stock for every Medtronic ordinary share tendered and accepted.

Medtronic caps the swap at the upper limit after shares priced above range

The company said the calculated per-share values of both Medtronic ordinary shares and MiniMed common stock, determined under the method set out in MiniMed's SEC-filed Prospectus, would have produced a ratio exceeding the deal's upper limit of 4.5939. Medtronic therefore locked the ratio at that ceiling, the maximum allowed under the offer's terms.

Orange County, Calif. – October 07, 2026 -- The Institute for Molecular Medicine (IMM) and Nuravax have dosed the first four participants in TAURUS-1980, a Phase 1 trial testing AV-1980R, described as the world's first active immunotherapy targeting pathological tau protein linked to Alzheimer's disease.

Trial targets at-risk adults before cognitive symptoms appear

TAURUS-1980 will enroll up to 48 cognitively unimpaired adults aged 65 to 80 who have biomarker-confirmed brain amyloid pathology, a known precursor to Alzheimer's. Participants are randomized 3:1 to receive AV-1980R or placebo across three ascending-dose cohorts of 20, 60, and 180 micrograms.

Sarasota, Fla. – October 07, 2026 -- Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) reported that its Bisphosphocin compound Nu-8, delivered intravesically to rodents infected with E. coli, achieved up to 97% inhibition of bacterial growth using a 10% solution, against no effect in a vehicle control group.

Nu-8 targets drug-resistant bacteria linked to catheter-associated UTIs

The Bisphosphocin class has shown in vitro activity against a broad range of resistant bacteria common in urinary tract infections, including E. coli, K. pneumoniae, and P. aeruginosa, and against biofilm-forming organisms. Complicated UTIs, particularly catheter-associated urinary tract infections, are frequently driven by drug-resistant strains and biofilm formation, a persistent challenge for hospital infection control.